Form 4: Agenus Inc. Director Timothy Wright Reports Stock Option Grant

Director Timothy Wright reports the acquisition of stock options in Agenus Inc. following shareholder approval.

Summary

• Timothy Wright, a director of Agenus Inc., filed a Form 4 disclosing changes in beneficial ownership.
• The report details the acquisition of 750 stock options on June 11, 2024, with an exercise price of $13.25.
• These options were initially granted on January 26, 2024, subject to shareholder approval, which was obtained on June 11, 2024.
• The options vest over three years, starting January 26, 2025, with one-third vesting initially and the remainder in equal quarterly installments.
• The stock options were granted prior to a 1 for 20 reverse stock split, originally representing 15,000 options with an exercise price of $0.66.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard compensation practices and alignment of interests. The grant itself is not unexpected.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, particularly in the biotech sector.
• Companies like Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.
• The vesting schedule of three years with quarterly installments is also a typical arrangement.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better decision-making.
• Employees may view the grant as a positive sign of the company's commitment to its leadership.

Key Dates